Welcome to our dedicated page for Horizon Space Acquisition II SEC filings (Ticker: HSPTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Horizon Space Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Horizon Space Acquisition II's regulatory disclosures and financial reporting.
Horizon Space Acquisition II Corp. outlines a PIPE financing to support its proposed business combination with SL BIO Ltd. and PubCo. PubCo has entered subscription agreements with PIPE investors to purchase an aggregate 780,000 PubCo units at $10.00 per unit, for expected gross proceeds of about $7,800,000 at the business combination closing.
Each unit includes one PubCo ordinary share and one series A preferred share that converts into one-third of a PubCo ordinary share six months after closing. PubCo will file a resale registration statement for the ordinary and conversion shares, and PIPE investors have agreed to a six‑month lock-up after the PIPE closing, subject to customary exceptions and to the business combination closing.
Horizon Space Acquisition II Corp. entered into a new unsecured promissory note for $50,000 with William Wang to fund an extension fee, allowing its initial business combination deadline to move from March 18, 2026 to April 18, 2026. This is the second of up to twelve one‑month extensions permitted under its charter amendment, which can push the deadline to February 18, 2027.
The note bears no interest and is due upon either completion of the business combination or the company’s expiry date. William Wang, Chief Executive Officer of SL BIO Ltd., may elect to convert the $50,000 note into Horizon Space private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one‑tenth of an ordinary share.
Wolverine Asset Management, Wolverine Holdings, Christopher L. Gust, and Robert R. Bellick filed Amendment No. 1 to a Schedule 13G/A reporting their relationship to Horizon Space Acquisition II Corp. The filing states each filer has 0% beneficial ownership and no sole or shared voting or dispositive power over the issuer's ordinary shares. The cover shows 02/24/2026; signatures are dated 02/27/2026. The issuer's principal executive office address is listed as 1412 Broadway, 21st Floor, Suite 21V, New York, NY 10018.
Horizon Space Acquisition II Corp. reports shareholder approvals that advance its planned merger with SL BIO Ltd. and extend its deadline to complete a business combination. Investors approved the business combination with SL Bio, related governance changes at PubCo, and the appointment of William Wang Ching-Dong as sole director effective at the first merger’s closing.
In a separate meeting, shareholders approved amendments to Horizon’s charter and trust agreement so the company can extend its February 18, 2026 termination date in up to twelve one‑month increments to February 18, 2027, funded by monthly deposits into the trust account of the lesser of $50,000 or $0.033 per remaining public share.
Horizon Space Acquisition II Corp. received an updated Schedule 13G/A (Amendment No. 3) from Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. stating that they now beneficially own 0 ordinary shares, representing 0% of the company’s ordinary shares.
The reporting entities disclose no sole or shared voting power and no sole or shared dispositive power over Horizon Space Acquisition II Corp. shares. They also indicate that they own 5 percent or less of the class, confirming that they are no longer significant shareholders and that any prior position has effectively been reduced to zero.
Horizon Space Acquisition II Corp. (HSPT) filed an 8-K to supplement its proxy materials for the February 12, 2026 business combination meeting with SL BIO Ltd. The update mainly adds two independent director nominees for the post-merger public company, SL Science Holding Limited (PubCo): Joseph Levinson and Qian (Hebe) Xu.
The filing also refreshes the expected beneficial ownership table for PubCo. Assuming 566,591,350 ordinary shares outstanding in a no-redemption scenario (and 559,956,923 in a maximum-redemption scenario), SL Link Holding Ltd., associated with William Wang, is expected to hold 333,832,129 shares, representing about 58.9% to 59.6% of PubCo’s voting power. Qian Xu is expected to beneficially own 20,000 shares.
The schedule and logistics for the business combination meeting remain unchanged. The meeting is set for 9:00 a.m. Eastern Time on February 12, 2026, with a redemption deadline of 5:00 p.m. Eastern Time on February 10, 2026, and shareholders of record as of December 29, 2025 remain entitled to vote.
Horizon Space Acquisition II Corp. filed an 8-K describing a press release that clarifies how public shareholders can redeem their shares around its proposed business combination with SL BIO Ltd. and related extension proposals.
Shareholders who already submitted redemption requests for the February 12, 2026 Business Combination Meeting and want their public shares redeemed whether the business combination closes or the extension is approved must instruct the transfer agent to redeem those shares for the Extension Proposals by 5:00 p.m. Eastern Time on February 11, 2026.
If the Extension Meeting on February 13, 2026 is not held and the Extension Proposals are not implemented, any shares submitted for redemption for both meetings will be redeemed upon consummation of the business combination unless the holder withdraws the request. The filing confirms there is no change to the time, location, record date or proposals for the Business Combination Meeting.
Horizon Space Acquisition II Corp. is asking shareholders to approve amendments to its charter and trust agreement at a February 13, 2026 extraordinary meeting. These changes would let the SPAC extend its deadline to complete an initial business combination, including the proposed SL Bio merger, from February 18, 2026 up to February 18, 2027 through up to twelve one‑month extensions.
For each monthly extension, the sponsor or its designee would deposit the lesser of $50,000 or $0.033 per remaining public share into the trust account. Public shareholders may redeem some or all public shares in connection with the extension vote for cash equal to their pro rata portion of the trust, which was about $10.53 per share as of December 29, 2025, compared with a Nasdaq closing price of $10.55 that day. If the extension is not approved and no deal closes by the current deadline (or existing extensions), the company may redeem all public shares and liquidate, and the rights in the units would expire worthless.
Horizon Space Acquisition II Corp. (HSPT) has postponed its extraordinary general meeting to approve the proposed business combination with SL BIO Ltd. The meeting, originally set for February 3, 2026, is rescheduled to February 12, 2026 at 9:00 a.m. Eastern Time to allow more time to engage with shareholders.
The record date remains December 29, 2025, so only shareholders of that date may vote. The deadline for public shareholders to submit redemption requests is extended to 5:00 p.m. Eastern Time on February 10, 2026. The meeting location and all proposals in the previously mailed definitive proxy statement are unchanged.